Ozon Pharmaceuticals Company is placing 78.5 million shares at ₽42 per share as part of the second stage of the SPO. Of these, 65.9 million shares will be repurchased with funds from the SPO and transferred to Pavel Aleksenko, the company's founder, in return for those sold during the SPO. Remaining 12.6 million are reserved for repurchase by the shareholders of Ozon Pharmaceuticals as of June 30, 2025 through the pre-emptive right mechanism. It is planned to complete the share placement by October 9th.